New challenges in Cardiology: stem cells and COVID-19

Zoltán Papp

University of Debrecen Department of Cardiology Division of Clinical Physiology Debrecen, Hungary

Can we rescue the damaged heart with stem cells?



For Heart Attack, Heart Failure & Bypass Patients

CHRISTIAN WILDE

Myocyte number declines by <u>one third</u> during the lifespan of humans

Myocyte death Ayocyte renewal

- Necrosis

Olivetti et al., Circ. Res. 68, 1560–1568, 1991.

Myocardial infarction is associated with massive cell loss



Cardiac aging is reflected in the decrease in cardiac reserve



Goldspink et al., Exp. Physiol. 88, 447–458, 2003.

Physiological cardiomyocyte renewal

Cardiomyocyte duplication



Differentiation from cardiac progenitor cells



Chimenti et al., Circ. Res. 93: 604-613, 2003

Srivastava & Ivey Nature 441, 1097-1099, 2006

Zebrafish has higher cardiac regenerative potential than human



Cardiac progenitor stem cells have high regenerative potential only after birth

Characterization and functionality of cardiac progenitor cells in congenital heart patients

Mishra et al. Circulation 123 (2011)

Transient Regenerative Potential of the Neonatal Mouse Heart

Enzo R. Porrello, et al. Science 331, 1078 (2011)



Cardiac mass and cardiomyocyte number during aging

Myocyte death Myocyte renewal

- Apoptosis
- Necrosis

- Differentiation of cardiac progenitor cells
- Cardiomyocyte duplication

Tissue heterogeneity and stem-cell functionality for homeostais and repair



Stem cells



Embrionic stem cells have a high proliferative potential

Embrionic stem cells



Adult stem cells can also differentiate into cardiomyocytes

Adult stem cells / Somatic stem cells



iPS induced pluripotent stem cells

Pluripotency induced by transcription factors (Yamanaka)



Potential stem cells for myocardial regeneration



Hematopoietic stem cell application following myocardial infarctions in humans



Intracoronary administration of BMCs



Drastic donor cell death within 4–5 weeks (bioluminescence imaging)



van der Bogt et al. Transplantation. 2009 87(5): 642-652.

Salvage of the damaged myocardium: paracrine effects?

Stem cells as "providers", "biofactories"



Evolution of clinical approaches



Future directions of myocardial cell therapy



Copland et al. Semin Immunopathol. 2011 33(6):535-50.

SARS-CoV-2 coronavirus



SARS-CoV-2 Inventory



- Proteins: Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N), Hemagglutinin esterase
- (He)
- Genome: 29,900 nucleotides of RNA

The clinical course of COVID-19







What makes SARS-CoV-2 a terminator?



SARS-CoV-2 Literature



| Quick Navigation Guide | SA | ARS-CoV-2 Da | 2 Data | |
|----------------------------|-----------|--------------------|--------------------|--|
| Sequence Submission | 0.047.540 | 4 674 667 | 7 074 | |
| Literature | 3,617,518 | 4,674,037 | 7,871 | |
| Sequence-Related Resources | SRA runs | Nucleotide records | ClinicalTrials.gov | |
| Clinical Resources | 249,86 | 56 3 . | 318,925 | |
| Other Websites | PubMed | | PMC | |

Submit SARS-CoV-2 Sequences



Add assembled & raw read data to the growing public archive

Submit Now

Cardiovascular involvement in COVID-19—key manifestations and hypothetical mechanisms



Guzik et al., Cardiovascular Research (2020) 116, 1666–1687

damage

Mantra of COVID-19





Underlying conditions among adults hospitalized with COVID-19

Note: Based on data from the COVID-19–Associated Hospitalization Surveillance Network for patients hospitalized in 99 counties in 14 states from March 1-30, 2020.

Source: MMWR. 2020 Apr 8:69(early release):1-7

Elderly patients with severe aortic stenosis have increased ACE2 activity



Fagyas et al. Geroscience. 2021 Jan 20:1-11.

Mild or severe COVID-19, that is the question



Cleary et al., Br J Pharmacol. 2020;177:4851-4865.

SARS-CoV-2 spike protein





Wanner Tech Corner February 01, 2021

Vaccination against COVID-19 in Europe



Cumulative vaccine uptake (%) in the total population in EU/EEA countries

| At least one dose | Primary course | Booster/additional dose |
|-------------------|----------------|-------------------------|
| 75.3% | 72.6% | 53.1% |

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-04-21

by reporting week (data for the current week are preliminary)



Covid vaccine skepticism



What are the side effects and risks?



*mRNA vaccines only **AstraZeneca and Janssen

The relationship between COVID vaccination and mortality



Source: ECDC, November 2021

US Covid deaths by vaccination status

Rate of coronavirus deaths per 100,000 people by week



BBC

Data from 25 participating health departments

Source: US Centers for Disease Control and Prevention (CDC), 17 Dec

THANK YOU FOR YOUR ATTENTION!





European Union European Regional Development Fund



INVESTING IN YOUR FUTURE

Hungarian Government